Introduction: The PI3/Akt/mTOR pathway is activated by IGF-1 in NETs. mTOR regulates signalling downstream of IGF-1R1: Afinitor and Sandostatin may synergistically arrest growth and secretory activity in NETs.
Aim(s): The Afinitor (mTOR inhibitor) particular patient supplies program treated 40 patients with advanced NETs in the UK from May 2008 to December 2010.
Materials and methods: The incidence of NETs is rising with rates approaching three per 100,000 (Ramage et al, Gut, 2005). Novartis Oncology UK provided the oral mTOR inhibitor, Afinitor, for unsolicited requests to patients with advanced NETs.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Mr Jonathan S Chambers
To read results and conclusion, please login ...
Further abstracts you may be interested in